Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2011
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Copper-64 trastuzumab PET imaging: a reproducibility study.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2019Trial
- Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- First-in-Man Evaluation ofMolecular imagingTrial
- Establishment ofMolecular pharmaceutics · 2026Article
- Diverse Roles of Antibodies in Antibody-Drug Conjugates.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a BivalentJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- Crystal structures and molecular dynamics simulations of a humanised antibody fragment at acidic to basic pH.Scientific reports · 2023Article
- Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.Molecular cancer therapeutics · 2022Article
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
- Antibody-Based Immunotoxins for Colorectal Cancer Therapy.Biomedicines · 2021Review
- Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.RSC advances · 2021Review
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Receptor Occupancy Imaging Studies in Oncology Drug Development.The AAPS journal · 2018Review
- I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.EJNMMI research · 2018Article
- Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer.Molecular imaging and radionuclide therapy · 2017Article
- Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.European journal of nuclear medicine and molecular imaging · 2016Article
- PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.European journal of nuclear medicine and molecular imaging · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThe primary aim of this analysis was to examine the quantitative features of antibody-antigen interactions in tumors and normal tissue after parenteral administration of antitumor antibodies to human patients.
methodsHumanized anti-A33 antibody (10 mg) labeled with the positron-emitting radionuclide (124)I ((124)I-huA33) was injected intravenously in 15 patients with colorectal cancer. Clinical PET/CT was performed approximately 1 wk later, followed by a detailed assay of surgically removed tissue specimens including radioactivity counting, autoradiography, immunohistochemistry, and antigen density determination.
resultsPET/CT showed high levels of antibody targeting in tumors and normal bowel. In tissue specimens, the spatial distribution of (124)I-huA33 conformed to that of A33 antigen, and there was a linear relationship between the amount of bound antibody and antigen concentration. Antibody uptake was high in 1- to 2-mm regions of antigen-positive tumor cells (mean, ~0.05 percentage injected dose per gram) and in antigen-positive normal colonic mucosa (mean, ~0.03 percentage injected dose per gram). The estimated binding site occupancy for tumor and normal colon was 20%-50%.
conclusionThe in vivo biodistribution of (124)I-huA33 in human patients 1 wk after antibody administration was determined by A33 antigen expression. Our data imply that the optimal strategy for A33-based radioimmunotherapy of colon cancer will consist of a multistep treatment using a radionuclide with short-range (α- or β-particle) emissions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.